Boston, June 21, 2025 — SyntecBio, a trailblazer in artificial intelligence-powered biotechnology, officially announced the SyntecBio Digital Biotech Summit 2025, a global forum that will spotlight how AI is redefining the future of medicine. The summit will be held on September 18, 2025, at the Boston Convention & Exhibition Center, with virtual access available worldwide.
Positioned at the forefront of the AI-biotech intersection, the one-day event is expected to gather over 500 industry leaders, including AI researchers, pharmaceutical executives, policy makers, and startup founders. Organizers say the summit will focus on how machine learning and synthetic biology are transforming the speed, scale, and precision of drug development.
A New Era for Digital Biotech
“Digital biotech is no longer just a research topic—it’s a commercial reality,” said Dr. Alicia Moreno, CEO of SyntecBio. “We launched this summit to bring together innovators, regulators, and investors who are actively reshaping the healthcare ecosystem through AI.”
The 2025 edition of the summit will explore four core pillars:
- AI-Enhanced Drug Discovery: Use cases of machine learning for molecular modeling, hit prediction, and trial design.
- Synthetic Biology Automation: From lab robots to AI-designed microbial strains.
- Regulatory Innovation & Ethics: How agencies are adapting frameworks for AI-powered treatments.
- Digital Therapeutics & Patient Platforms: Personalized treatment algorithms and remote diagnostics.
Key Sessions & Participants
- Opening Keynote: “AI vs. Superbugs: The New Frontier in Antibiotics” by Dr. Michael Tanaka, CSO, Novartica Pharmaceuticals.
- Tech Demo: Live showcase of NEURADapt™, SyntecBio’s adaptive cancer therapy design engine.
- Panel Discussion: “AI Ethics in Precision Medicine” featuring speakers from the U.S. FDA, World Bioethics Institute, and Harvard Medical School.
- Startup Pitch Arena: 15 emerging digital biotech firms will present to investors and pharma scouts.
Industry Context
The announcement comes at a time when AI-driven R&D is accelerating across the pharmaceutical sector. According to SyntecBio, its flagship platform NEURADapt™ has already helped cut development time by up to 40% in preclinical oncology trials.
“Platforms like NEURADapt aren’t just about automation—they represent a new logic in how we approach biology,” said Dr. Lena Hughes, Chief Technology Officer at SyntecBio.
Event Details
- Date: Thursday, September 18, 2025
- Time: 9:00 AM – 6:00 PM EST
- Location: Boston Convention & Exhibition Center, 415 Summer Street, Boston, MA
- Registration: www.syntecbio.com/ (Early bird tickets available through August 15)
- Virtual Access: Global streaming and AI-moderated Q&A included
About SyntecBio
Founded in 2019, SyntecBio is a Boston-based biotech company leveraging artificial intelligence to accelerate drug discovery, optimize biologics development, and expand access to precision therapeutics. Its proprietary technologies are currently being deployed in collaborative trials with multiple U.S. cancer research institutions.
